Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

M. Mohty, K. Hübel, N. Kröger, M. Aljurf, J. Apperley, GW. Basak, A. Bazarbachi, K. Douglas, I. Gabriel, L. Garderet, C. Geraldes, O. Jaksic, MW. Kattan, Z. Koristek, F. Lanza, RM. Lemoli, L. Mendeleeva, G. Mikala, N. Mikhailova, A. Nagler, HC....

. 2014 ; 49 (7) : 865-72.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc15023509
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Medline Complete (EBSCOhost) from 1997-01-01 to 2015-11-30
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 24686988
DOI 10.1038/bmt.2014.39
Knihovny.cz E-resources

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023509
003      
CZ-PrNML
005      
20240528140904.0
007      
ta
008      
150709s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bmt.2014.39 $2 doi
035    __
$a (PubMed)24686988
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mohty, Mohamad $u Department of Haematology, Saint Antoine Hospital, Paris, France. $7 xx0317729
245    10
$a Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation / $c M. Mohty, K. Hübel, N. Kröger, M. Aljurf, J. Apperley, GW. Basak, A. Bazarbachi, K. Douglas, I. Gabriel, L. Garderet, C. Geraldes, O. Jaksic, MW. Kattan, Z. Koristek, F. Lanza, RM. Lemoli, L. Mendeleeva, G. Mikala, N. Mikhailova, A. Nagler, HC. Schouten, D. Selleslag, S. Suciu, A. Sureda, N. Worel, P. Wuchter, C. Chabannon, RF. Duarte,
520    9_
$a Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.
650    _2
$a mobilizace hematopoetických kmenových buněk $x metody $7 D019650
650    _2
$a lidé $7 D006801
650    _2
$a lymfom $x terapie $7 D008223
650    _2
$a mnohočetný myelom $x terapie $7 D009101
650    _2
$a autologní transplantace $7 D014182
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Hübel, K $u University Hospital Cologne, Cologne, Germany.
700    1_
$a Kröger, N $u University Hospital Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Aljurf, M $u King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabi. $7 gn_A_00004326
700    1_
$a Apperley, J $u Imperial College London, London, UK. $7 gn_A_00007841
700    1_
$a Basak, G W $u The Medical University of Warsaw, Warsaw, Poland.
700    1_
$a Bazarbachi, A $u American University of Beirut, Beirut, Lebanon.
700    1_
$a Douglas, K $u Beatson West of Scotland Cancer Centre, Glasgow, UK.
700    1_
$a Gabriel, I $u Imperial College London, London, UK.
700    1_
$a Garderet, L $u Department of Haematology, Saint Antoine Hospital, Paris, France.
700    1_
$a Geraldes, C $u University Hospital Coimbra, Coimbra, Portugal.
700    1_
$a Jaksic, O $u University Hospital Dubrava, Zagreb, Croatia.
700    1_
$a Kattan, M W $u Quantitative Health Sciences Cleveland Clinic, Cleveland, OH, USA.
700    1_
$a Koristek, Z $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Lanza, F $u Cremona Hospital, Cremona, Italy.
700    1_
$a Lemoli, R M $u University of Genoa, Genoa, Italy.
700    1_
$a Mendeleeva, L $u National Research Centre for Haematology, Moscow, Russia.
700    1_
$a Mikala, G $u St Istvan and St Laszlo Hospital, Budapest, Hungary.
700    1_
$a Mikhailova, N $u Institute of Children Haematology and Transplantation n.a. R Gorbacheva, St Petersburg State Pavlov Medical University, St Petersburg, Russia.
700    1_
$a Nagler, A $u Chaim Sheba Medical Center, Tel Hashomer, Israel.
700    1_
$a Schouten, H C $u Maastricht University Medical Centre, Maastricht, The Netherlands.
700    1_
$a Selleslag, D $u Department of Haematology, AZ Sint-Jan, Brugge-Oostende, Belgium.
700    1_
$a Suciu, S $u EORTC Headquarters, Brussels, Belgium.
700    1_
$a Sureda, A $u Addenbrooke's Hospital, Cambridge, UK.
700    1_
$a Worel, N $u Medical University Vienna, Vienna, Austria.
700    1_
$a Wuchter, P $u Department of Medicine V, Heidelberg University, Heidelberg, Germany.
700    1_
$a Chabannon, C $u Institut Paoli-Calmettes and Inserm CBT-510, Marseille, France.
700    1_
$a Duarte, R F $u Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 49, č. 7 (2014), s. 865-72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24686988 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20240528140900 $b ABA008
999    __
$a ok $b bmc $g 1083846 $s 906502
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 49 $c 7 $d 865-72 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options